Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study | BMC Cardiovascular Disorders
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
2 1 Intensification strategies
VisualAbstract: Ticagrelor non-superior to clopidogrel in the reduction of PCI-related myocardial necrosis | 2 Minute Medicine
JCM | Free Full-Text | De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature | HTML
Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health - Journal of Cardiology
Transition between ticagrelor and two different doses of clopidogrel at hospital discharge in patients with acute coronary syndrome submitted to percutaneous coronary intervention - ScienceDirect
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy - Canadian Journal of Cardiology
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI | JACC: Cardiovascular Interventions
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports
Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial | Trials | Full Text
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada - CJC Open
Ticagrelor Dosage Guide + Max Dose, Adjustments - Drugs.com
2 3 De escalation strategies
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy - Canadian Journal of Cardiology
Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | tctmd.com
Brilinta (Ticagrelor Tablets for Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning
Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark - The Lancet Regional Health – Europe
Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week - ScienceDirect
Dr. Sheila Sahni on Twitter: "Algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting. (For the Figure: LD = loading dose; MD = maintenance dose) Source: 2017 ESC
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet
Figure 1 from Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. | Semantic Scholar
Double Versus Standard Loading Dose of Ticagrelor: Onset of Antiplatelet Action in Patients With STEMI Undergoing Primary PCI | Journal of the American College of Cardiology
Antiplatelet therapy in coronary artery disease
JCM | Free Full-Text | Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial | HTML
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI - ScienceDirect
